HOME >> MEDICINE >> NEWS
Artificial liver moves toward commercialization

Emergency device could save lives

SAN FRANCISCO -- In cases of severe liver failure, often the only effective alternative to keep a patient alive is a liver transplant. Due to a severe shortage of donor organs, many patients die waiting for suitable organs. An artificial liver that provides temporary support of a person's liver function can serve as a bridge to transplant or as a short-term treatment. Prototype devices, which filter blood toxins that build up as a result of liver damage, have been used in limited clinical trials to support patients. Advances in the development of this device, which could save many lives in the future, will be highlighted at the 219th national meeting of the American Chemical Society, the world's largest scientific society.

  • Upgraded device awaits human trials: The University of Minnesota bioartificial liver is among the earliest prototype devices still under development. To make it function longer than other models, researchers are using freshly isolated pig liver cells -- believed to work better than frozen liver cells -- as the substitute chemical-processing unit for the patient's liver. The first human clinical trials of this prototype device are scheduled to begin soon, pending U. S. Food and Drug Administration approval, among several patients with severe liver failure. (D. N. Adams, University of Minnesota, Minneapolis, Minn.; BIOT 81; Monday, March 27, 4:25 p.m.; Moscone Convention Center, Room 300, Esplanade Level. See page 68 in the final program.)

  • Improving device performance: Artificial livers currently being tested employ straight-line hollow fiber bioreactors to house the chemical-processing cells that substitute for the human liver. Such devices are subject to clogging and transport difficulties, resulting in poor transport of nu
    '"/>


Contact: charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
26-Mar-2000


Page: 1 2

Related medicine news :

1. Artificial liver trials show progress, as transplant candidates wait
2. Artificial organs
3. New Type Of Artificial Surfactant Shows Promise In Treating Lung Disease
4. Trial Begins For First Artificial Liver Device Using Human Cells
5. Research offers hope of new treatments for liver damage
6. Success of liver transplantation may be most influenced by three risk factors
7. Alcohol relapse adversely affects 10-year liver transplant survival
8. Donor age has no affect on long-term liver transplant survival
9. NHS stop-smoking services are insufficient to deliver national smoking targets
10. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
11. Component of green tea protects injured livers in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Artificial liver moves toward commercialization

(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
(Date:5/24/2013)... Bay, Australia (PRWEB) May 24, 2013 ... show off their favorite sunglasses all while learning ... longer with replacement lenses. Contestants only need ... wearing their sunglasses and "like" The Sunglass Fix ... winning Sunglass fix is the largest lens ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... In a coup that surely made other ... of the Estetica Institute of the Palm Beaches performed eye ... popular morning show, “The Mo & Sally Morning Show.” The ... satisfaction with the results, giving Dr. DeLange and the team ... Beach Gardens, very valuable free publicity. , Dr. DeLange, the ...
(Date:5/24/2013)... 2013 CBT News.com recently announced the addition ... web-based retail automotive industry news organization with 12 years experience ... to join a group that’s so forward-thinking in their approach,” ... online video content is on the rise.” , Atlanta born ... and segued into advertising at Cycle News and Boating World. ...
Breaking Medicine News(10 mins):Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Dr. Greg DeLange of the Estetica Institute Recently Performed Eye Surgery on Both Members of Popular Morning Radio Team 2
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... 23, 2013 Amgen (NASDAQ: AMGN ) ... Healthcare Conference on Thursday, May 30, 2013, at the Westin ... 9:20 a.m. Eastern Daylight Time. Arvind Sood ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: